Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

By Sandi Wong, Assistant Editor and Paul Bonanos, Associate Editor

Nov 25, 2020 | 11:32 PM GMT

FDA approves Y-mAbs’ Danyelza for neuroblastoma
Shares of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) were up 17% in after-hours trading Wednesday after FDA granted accelerated approval to Danyelza naxitamab-gqgk